214 related articles for article (PubMed ID: 24497984)
1. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.
Megison ML; Gillory LA; Stewart JE; Nabers HC; Mroczek-Musulman E; Waters AM; Coleman JM; Kelly V; Markert JM; Gillespie GY; Friedman GK; Beierle EA
PLoS One; 2014; 9(1):e86843. PubMed ID: 24497984
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma.
Gillory LA; Megison ML; Stewart JE; Mroczek-Musulman E; Nabers HC; Waters AM; Kelly V; Coleman JM; Markert JM; Gillespie GY; Friedman GK; Beierle EA
PLoS One; 2013; 8(10):e77753. PubMed ID: 24130898
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.
Friedman GK; Bernstock JD; Chen D; Nan L; Moore BP; Kelly VM; Youngblood SL; Langford CP; Han X; Ring EK; Beierle EA; Gillespie GY; Markert JM
Sci Rep; 2018 Sep; 8(1):13930. PubMed ID: 30224769
[TBL] [Abstract][Full Text] [Related]
4. Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy.
Kim Y; Saini U; Kim D; Hernandez-Aguirre I; Hedberg J; Martin A; Mo X; Cripe TP; Markert J; Cassady KA; Dhital R
Front Immunol; 2024; 15():1375413. PubMed ID: 38895115
[TBL] [Abstract][Full Text] [Related]
5. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
Friedman GK; Moore BP; Nan L; Kelly VM; Etminan T; Langford CP; Xu H; Han X; Markert JM; Beierle EA; Gillespie GY
Neuro Oncol; 2016 Feb; 18(2):227-35. PubMed ID: 26188016
[TBL] [Abstract][Full Text] [Related]
6. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.
Jackson JD; McMorris AM; Roth JC; Coleman JM; Whitley RJ; Gillespie GY; Carroll SL; Markert JM; Cassady KA
Gene Ther; 2014 Nov; 21(11):984-90. PubMed ID: 25119379
[TBL] [Abstract][Full Text] [Related]
7. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography imaging with
Kasten BB; Houson HA; Coleman JM; Leavenworth JW; Markert JM; Wu AM; Salazar F; Tavaré R; Massicano AVF; Gillespie GY; Lapi SE; Warram JM; Sorace AG
Sci Rep; 2021 Jul; 11(1):15384. PubMed ID: 34321569
[TBL] [Abstract][Full Text] [Related]
9. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
[TBL] [Abstract][Full Text] [Related]
10. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
Hong B; Sahu U; Mullarkey MP; Kaur B
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
Fu X; Nakamori M; Tao L; Amato R; Zhang X
Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
[TBL] [Abstract][Full Text] [Related]
12. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
Parker JN; Gillespie GY; Love CE; Randall S; Whitley RJ; Markert JM
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2208-13. PubMed ID: 10681459
[TBL] [Abstract][Full Text] [Related]
13. Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma.
Waters AM; Stafman LL; Garner EF; Mruthyunjayappa S; Stewart JE; Friedman GK; Coleman JM; Markert JM; Gillespie GY; Beierle EA
Transl Oncol; 2016 Oct; 9(5):419-430. PubMed ID: 27751346
[TBL] [Abstract][Full Text] [Related]
14. VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.
Eshun FK; Currier MA; Gillespie RA; Fitzpatrick JL; Baird WH; Cripe TP
Gene Ther; 2010 Jul; 17(7):922-9. PubMed ID: 20508601
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
[TBL] [Abstract][Full Text] [Related]
16. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
[TBL] [Abstract][Full Text] [Related]
17. Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV.
Wang PY; Currier MA; Hansford L; Kaplan D; Chiocca EA; Uchida H; Goins WF; Cohen JB; Glorioso JC; van Kuppevelt TH; Mo X; Cripe TP
Gene Ther; 2013 Jul; 20(7):761-9. PubMed ID: 23254370
[TBL] [Abstract][Full Text] [Related]
18. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
19. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.
Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL
Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870
[TBL] [Abstract][Full Text] [Related]
20. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
